145 related articles for article (PubMed ID: 35884583)
1. Real-World Evaluation of Quality of Life, Effectiveness, and Safety of Aflibercept Plus FOLFIRI in Patients with Metastatic Colorectal Cancer: The Prospective QoLiTrap Study.
Hofheinz RD; Anchisi S; Grünberger B; Derigs HG; Zahn MO; Geffriaud-Ricouard C; Gueldner M; Windemuth-Kieselbach C; Pederiva S; Bohanes P; Scholten F; Piringer G; Thaler J; von Moos R
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884583
[TBL] [Abstract][Full Text] [Related]
2. Quality of life, effectiveness, and safety of aflibercept plus FOLFIRI in older patients with metastatic colorectal cancer: An analysis of the prospective QoLiTrap study.
Piringer G; Thaler J; Anchisi S; Geffriaud-Ricouard C; Gueldner M; Scholten F; Derigs HG; Bohanes P; Grünberger B; Schwarz L; von Moos R; Hofheinz RD
J Geriatr Oncol; 2023 Nov; 14(8):101638. PubMed ID: 37776611
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Second-line Anti-VEGF after First-line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter "SLAVE" Study.
Parisi A; Cortellini A; Cannita K; Venditti O; Camarda F; Calegari MA; Salvatore L; Tortora G; Rossini D; Germani MM; Boccaccino A; Dell'Aquila E; Fulgenzi C; Santini D; Tursi M; Tinari N; Marino PD; Lombardi P; Keränen SR; Álvaro MH; Zurlo IV; Corsi DC; Emiliani A; Zanaletti N; Troiani T; Vitale P; Giampieri R; Merloni F; Occhipinti MA; Marchetti P; Roberto M; Mazzuca F; Ghidini M; Indini A; Garajova I; Zoratto F; Monache SD; Porzio G; Ficorella C
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32429380
[TBL] [Abstract][Full Text] [Related]
4. Quality of Life Analysis in Patients With RAS Wild-Type Metastatic Colorectal Cancer Treated With First-Line Cetuximab Plus Chemotherapy.
Yamaguchi K; Ando M; Ooki A; Beier F; Guenther S; von Hohnhorst P; Van Cutsem E
Clin Colorectal Cancer; 2017 Jun; 16(2):e29-e37. PubMed ID: 28081962
[TBL] [Abstract][Full Text] [Related]
5. Study protocol for HGCSG1801: A multicenter, prospective, phase II trial of second-line FOLFIRI plus aflibercept in patients with metastatic colorectal cancer refractory to anti-EGFR antibodies.
Nakatsumi H; Komatsu Y; Muranaka T; Yuki S; Kawamoto Y; Harada K; Dazai M; Tateyama M; Sasaki Y; Miyagishima T; Tsuji Y; Katagiri M; Nakamura M; Sogabe S; Hatanaka K; Meguro T; Kobayashi T; Ishiguro A; Muto O; Shindo Y; Kotaka M; Ando T; Takagi R; Sakamoto N; Sakata Y
Front Oncol; 2022; 12():939425. PubMed ID: 36439491
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, safety, and cost-effectiveness analysis of aflibercept in metastatic colorectal cancer: A rapid health technology assessment.
Ge P; Wan N; Han X; Wang X; Zhang J; Long X; Wang X; Bian Y
Front Pharmacol; 2022; 13():914683. PubMed ID: 36110513
[No Abstract] [Full Text] [Related]
7. Is aflibercept an optimal treatment for wt RAS mCRC patients after progression to first line containing anti-EGFR?
Vera R; Mata E; González E; Juez I; Alonso V; Iranzo P; Martínez NP; López C; Cabrera JM; Safont MJ; Ruiz-Casado A; Salgado M; González B; Escudero P; Rivera F; Pericay C
Int J Colorectal Dis; 2020 Apr; 35(4):739-746. PubMed ID: 32062727
[TBL] [Abstract][Full Text] [Related]
8. FOLFIRI plus BEvacizumab or aFLIbercept after FOLFOX-bevacizumab failure for COlorectal cancer (BEFLICO): An AGEO multicenter study.
Torregrosa C; Pernot S; Vaflard P; Perret A; Tournigand C; Randrian V; Doat S; Neuzillet C; Moulin V; Stouvenot M; Roth G; Darbas T; Auberger B; Godet T; Jaffrelot M; Lambert A; Dubreuil O; Gluszak C; Bernard-Tessier A; Turpin A; Palmieri LJ; Bouche O; Goujon G; Lecomte T; Sefrioui D; Locher C; Grados L; Gignoux P; Trager S; Nassif E; Saint A; Hammel P; Lecaille C; Bureau M; Perrier M; Botsen D; Bourgeois V; Taieb J; Auclin E
Int J Cancer; 2022 Dec; 151(11):1978-1988. PubMed ID: 35833561
[TBL] [Abstract][Full Text] [Related]
9. Protocol of the EFFORT study: a prospective study of FOLFIRI plus aflibercept as second-line treatment after progression on FOLFOXIRI plus bevacizumab or during maintenance treatment in patients with unresectable/metastatic colorectal cancer.
Satake H; Ando K; Oki E; Shimokawa M; Makiyama A; Saeki H; Tsuji A; Mori M
BMC Cancer; 2020 Nov; 20(1):1116. PubMed ID: 33203393
[TBL] [Abstract][Full Text] [Related]
10. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
Van Cutsem E; Tabernero J; Lakomy R; Prenen H; Prausová J; Macarulla T; Ruff P; van Hazel GA; Moiseyenko V; Ferry D; McKendrick J; Polikoff J; Tellier A; Castan R; Allegra C
J Clin Oncol; 2012 Oct; 30(28):3499-506. PubMed ID: 22949147
[TBL] [Abstract][Full Text] [Related]
11. The Clinical and Cost Effectiveness of Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy (FOLFIRI) for the Treatment of Metastatic Colorectal Cancer Which has Progressed Following Prior Oxaliplatin-Based Chemotherapy: a Critique of the Evidence.
Wade R; Duarte A; Simmonds M; Rodriguez-Lopez R; Duffy S; Woolacott N; Spackman E
Pharmacoeconomics; 2015 May; 33(5):457-66. PubMed ID: 25616671
[TBL] [Abstract][Full Text] [Related]
12. A VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRI.
Chau I; Joulain F; Iqbal SU; Bridgewater J
BMC Cancer; 2014 Aug; 14():605. PubMed ID: 25142418
[TBL] [Abstract][Full Text] [Related]
13. Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study.
Pastorino A; Di Bartolomeo M; Maiello E; Iaffaioli V; Ciuffreda L; Fasola G; Di Costanzo F; Frassineti GL; Marchetti P; Antoniotti C; Leone F; Zaniboni A; Aprile G; Zilocchi C; Sobrero A; Bordonaro R
Clin Colorectal Cancer; 2018 Sep; 17(3):e457-e470. PubMed ID: 29605592
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and safety of aflibercept for metastatic colorectal cancer: retrospective review within an early access program in Spain.
Feliu J; Díez de Corcuera I; Manzano JL; Valladares-Ayerbes M; Alcaide J; García García T; Vera R; Sastre J
Clin Transl Oncol; 2017 Apr; 19(4):498-507. PubMed ID: 27718155
[TBL] [Abstract][Full Text] [Related]
15. Aflibercept Plus FOLFIRI as Second-Line Treatment for Metastatic Colorectal Cancer: A Single-Institution Real-Life Experience.
Lavacchi D; Roviello G; Giommoni E; Dreoni L; Derio S; Brugia M; Amedei A; Pillozzi S; Antonuzzo L
Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359764
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of FOLFIRI/aflibercept in second-line treatment of metastatic colorectal cancer in a real-world population: Prognostic and predictive markers.
Fernández Montes A; Martínez Lago N; Covela Rúa M; de la Cámara Gómez J; González Villaroel P; Méndez Méndez JC; Jorge Fernández M; Salgado Fernández M; Reboredo López M; Quintero Aldana G; Luz Pellón Augusto M; Graña Suárez B; García Gómez J
Cancer Med; 2019 Mar; 8(3):882-889. PubMed ID: 30690930
[TBL] [Abstract][Full Text] [Related]
17. Aflibercept in Combination With FOLFIRI as First-line Chemotherapy in Patients With Metastatic Colorectal Cancer (mCRC): A Phase II Study (FFCD 1302).
Lapeyre-Prost A; Pernot S; Sigrand J; Le Malicot K; Mary F; Aparicio T; Dahan L; Caroli-Bosc FX; Lecomte T; Doat S; Marthey L; Desrame J; Lepage C; Taieb J
Clin Colorectal Cancer; 2020 Dec; 19(4):285-290. PubMed ID: 32921581
[TBL] [Abstract][Full Text] [Related]
18. Safety and effectiveness of aflibercept in combination with FOLFIRI in Korean patients with metastatic colorectal cancer who received oxaliplatin-containing regimen.
Beom SH; Kim JG; Baik SH; Shin SH; Park I; Park YS; Lee MA; Lee S; Jeon SY; Han SW; Kang MH; Oh J; Kim JS; Kim JY; Ahn MS; Zang DY; Bae BN; Jo HJ; Kim HK; Kim JH; Yoon JA; Kim DH
J Cancer Res Clin Oncol; 2023 Mar; 149(3):1131-1143. PubMed ID: 35344080
[TBL] [Abstract][Full Text] [Related]
19. Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy.
Van Cutsem E; Joulain F; Hoff PM; Mitchell E; Ruff P; Lakomý R; Prausová J; Moiseyenko VM; van Hazel G; Cunningham D; Arnold D; Schmoll HJ; Ten Tije AJ; McKendrick J; Kröning H; Humblet Y; Grávalos C; Le-Guennec S; Andria M; Dochy E; Vishwanath RL; Macarulla T; Tabernero J
Target Oncol; 2016 Jun; 11(3):383-400. PubMed ID: 26706237
[TBL] [Abstract][Full Text] [Related]
20. Safety and Effectiveness of Aflibercept + Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) for the Treatment of Patients with Metastatic Colorectal Cancer (mCRC) in Current Clinical Practice: OZONE Study.
Chau I; Fakih M; García-Alfonso P; Linke Z; Ruiz Casado A; Marques EP; Picard P; Celanovic M; Cartwright T
Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32168980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]